Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 70 results for crohn's disease

  1. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

    HealthTech guidance
    Published
    17 February 2016
    View recommendations

    Sections for HTG401

  2. Inflammatory bowel disease (QS81)

    This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    26 February 2015
    View quality statements

    Sections for QS81

  3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  4. Leukapheresis for inflammatory bowel disease (HTG75)

    Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.

    HealthTech guidance
    Published
    22 June 2005
    View recommendations

    Sections for HTG75

  5. Spondyloarthritis in over 16s: diagnosis and management (NG65)

    This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.

    NICE guideline
    Last updated
    2 June 2017
    View recommendations

    Sections for NG65

  6. Wireless capsule endoscopy for investigation of the small bowel (HTG62)

    Evidence-based recommendations on wireless capsule endoscopy for investigation of the small bowel. This involves the person swallowing a small capsule containing a tiny camera that takes pictures as it passes through the body.

    HealthTech guidance
    Published
    15 December 2004
    View recommendations

    Sections for HTG62

  7. Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)

    Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).

    HealthTech guidance
    Published
    2 October 2013
    View recommendations

    Sections for HTG320

  8. 5-aminosalicylate (5-ASA) treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost effective than no treatment?

    treatment:- Following successful medical induction of remission of Crohn's disease of the colon, is mesalazine more clinically and cost...

    Research recommendation
    Published
    17 September 2020

  9. What are the benefits, risk and cost effectiveness of enteral nutrition in maintaining remission in the post-surgical period of Crohn's disease?

    period of Crohn's disease? Any explanatory notes(if applicable) The recommendations apply to people with ileocolonic Crohn's...

    Research recommendation
    Published
    25 October 2019

  10. Ulcerative colitis: management (NG130)

    This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.

    NICE guideline
    Published
    3 May 2019
    View recommendations

    Sections for NG130

  11. ProciseDx point-of-care platform for inflammatory bowel disease (MIB302)

    NICE has developed a medtech innovation briefing (MIB) on ProciseDx point-of-care platform for inflammatory bowel disease .

    Medtech innovation briefing
    Published
    12 July 2022

  12. SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea (HTG598)

    Evidence-based recommendations on SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea.

    HealthTech guidance
    Published
    17 November 2021
    View recommendations

    Sections for HTG598

  13. Further research is recommended to resolve the uncertainties about the long-term clinical effectiveness of darvadstrocel compared with standard care. In particular, estimates of long-term remission rates (minimum of 2 years' follow-up) in Crohn's disease with perianal fistulas are needed.

    estimates of long-term remission rates (minimum of 2 years' follow-up) in Crohn's disease with perianal fistulas are needed. Any...

    Research recommendation
    Published
    19 March 2019

  14. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  15. Topic prioritisation

    Find out what guidance is being considered for development